Breaking News Instant updates and real-time market news.

OPHT

Ophthotech

$43.57

-2.56 (-5.55%)

, REGN

Regeneron

$402.82

0.8 (0.20%)

10:26
10/04/16
10/04
10:26
10/04/16
10:26

Before the Move: Ophthotech worries seen as opportunity ahead of Phase 3 data

Regeneron Pharmaceuticals' (REGN) disappointing Phase 2 data evaluating aflibercept co-formulated with rinucumab in neovascular age-related macular degeneration, or AMD, released on Friday have been a drag on shares of Ophthotech (OPHT), which are down about 15% over the last few sessions. The latter is also focused on developing therapeutics for AMD, but JPMorgan analyst Anupam Rama believes the treatments being developed by the companies show "important differences." Further, the analyst recommended buying Ophthotech's shares amid the weakness ahead of its Phase 3 data, which is expected to be released before the end of the year. BACKGROUND: Ophthotech has initiated a pivotal Phase 3 clinical program to evaluate Fovista 1.5mg combination with anti-VEGF drugs compared to anti-VEGF monotherapy for the treatment of newly diagnosed patients with wet AMD, which is the more advanced type of the disease. Although it affects only 10%-15% of those who have the condition, it accounts for 90% of the severe vision loss caused by macular degeneration. BUY ON WEAKNESS: In a note to investors this morning, JPMorgan's Rama raised his price target for Ophthotech to $110 from $95, citing the elimination of its key competitor Regeneron from the Wet AMD space following its trial failure. Noting that Ophthotech's stock was down amid mechanism concerns following Regeneron's data, Rama said he views the weakness as a buying opportunity. Further, he sees "important mechanistic differences" between the company's Fovista and Regeneron's REGN2176-3, adding that early Phase 1 data for Fovista is "comparatively more compelling." Rama told investors that Ophthotech's Phase 3 results with Fovista and Lucentis combination therapy are expected this quarter, and reiterated an Outperform rating on the company's shares. COMPETITOR DATA: On Friday, Regeneron announced topline results from its Phase 2 CAPELLA study evaluating aflibercept co-formulated with rinucumab, an anti-platelet-derived growth factor receptor beta antibody, in patients with neovascular AMD. The combination therapy did not demonstrate an improvement in best corrected visual acuity compared to intravitreal aflibercept injection monotherapy at 12 weeks, the primary endpoint of the study. PRICE ACTION: In morning trading, shares of Ophthotech's shares have gained about 5.5% to $45.97, while Regeron's stock is flat near $402 per share. "Before the Move" is The Fly's recurring series of exclusive stories that identify potentially market moving events, along with analyst predictions, ahead of the news.

OPHT

Ophthotech

$43.57

-2.56 (-5.55%)

REGN

Regeneron

$402.82

0.8 (0.20%)

  • 30

    Oct

  • 29

    Mar

OPHT Ophthotech
$43.57

-2.56 (-5.55%)

06/02/16
JPMS
06/02/16
UPGRADE
Target $84
JPMS
Overweight
Ophthotech upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Ophthotech to Overweight saying the Fovista phase 3 Lucentis combination studies reading out in Q4 have a very high probability of success. The analyst's base case assumes a four-plus letter gain in visual acuity compared to Lucentis monotherapy, resulting in 55%-60% share upside. His "homerun scenario," or five-plus letter, results in 150% share upside. He raised his price target for Ophthotech shares to $84 from $60.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/30/16
COWN
09/30/16
NO CHANGE
Target $60
COWN
Outperform
Ophthotech price target lowered to $60 from $80 at Cowen
Cowen analyst Tyler Van Buren said that Regeneron's (REGN) Phase 2 data for aflibercept co-formulated with rinucumab is negative for the class of anti-PDGFs as a whole and lowered his price target on Ophthotech (OPHT) to $60 from $80 after lowering his view of the probability of the success of its own wet AMD treatment to 50%. However, if a 3-4 letter benefit if observed when the Phase III trials read out in December, upside of $80-$120 per share from current levels is still possible, said Van Buren, who keeps an Outperform rating on Ophthotech shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
REGN Regeneron
$402.82

0.8 (0.20%)

09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.

TODAY'S FREE FLY STORIES

SBCF

Seacoast Banking

$23.70

-0.53 (-2.19%)

14:33
02/21/17
02/21
14:33
02/21/17
14:33
Conference/Events
Seacoast Banking to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FXI

iShares Trust FTSE/Xinhua China 25 Fund

$38.76

0.3 (0.78%)

14:31
02/21/17
02/21
14:31
02/21/17
14:31
Options
Notable spreads in the Largecap China ETF »

Notable spreads in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEM

Newmont Mining

$37.35

0.34 (0.92%)

, WCN

Waste Connections

$83.81

0.2099 (0.25%)

14:29
02/21/17
02/21
14:29
02/21/17
14:29
Earnings
Notable companies reporting after market close »

Notable companies…

NEM

Newmont Mining

$37.35

0.34 (0.92%)

WCN

Waste Connections

$83.81

0.2099 (0.25%)

VRSK

Verisk Analytics

$84.90

0.63 (0.75%)

NFX

Newfield Exploration

$42.51

0.69 (1.65%)

KAR

KAR Auction

$46.55

0.07 (0.15%)

XPO

XPO Logistics

$48.60

-0.62 (-1.26%)

FSLR

First Solar

$34.84

0.73 (2.14%)

TXRH

Texas Roadhouse

$48.24

0.13 (0.27%)

TEX

Terex

$32.14

0.14 (0.44%)

PZZA

Papa John's

$86.01

-0.39 (-0.45%)

WLL

Whiting Petroleum

$11.61

0.5 (4.50%)

SPN

Superior Energy

$16.64

0.215 (1.31%)

DEPO

Depomed

$16.47

-0.38 (-2.26%)

RRGB

Red Robin

$47.80

0.05 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 24

    Feb

  • 26

    Feb

  • 01

    Mar

  • 05

    Mar

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 15

    Mar

CDE

Coeur Mining

$9.20

0.315 (3.55%)

14:26
02/21/17
02/21
14:26
02/21/17
14:26
Options
Coeur Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
02/21/17
02/21
14:25
02/21/17
14:25
General news
Canada Retail Sales Preview »

Canada Retail Sales…

14:25
02/21/17
02/21
14:25
02/21/17
14:25
Conference/Events
Leerink specialty pharma/biotech analysts hold analyst/industry conference call »

Specialty Pharmaceuticals…

VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

, TTM

Tata Motors

$34.20

0.74 (2.21%)

14:24
02/21/17
02/21
14:24
02/21/17
14:24
Periodicals
Volkswagen, Tata Motors in advanced partnership talks, Economic Times says »

Volkswagen (VLKAY) and…

VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

TTM

Tata Motors

$34.20

0.74 (2.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSR

Restaurant Brands

$57.56

3.66 (6.79%)

, PLKI

Popeyes

$66.12

-0.26 (-0.39%)

14:24
02/21/17
02/21
14:24
02/21/17
14:24
Periodicals
Popeyes declined rival bid from Arby's, Bloomberg reports »

Popeyes Louisiana Kitchen…

QSR

Restaurant Brands

$57.56

3.66 (6.79%)

PLKI

Popeyes

$66.12

-0.26 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 23

    Mar

14:21
02/21/17
02/21
14:21
02/21/17
14:21
General news
Stocks drifting near all-time best levels »

Stocks remain in positive…

$NSD

NASDAQ Market Internals

14:18
02/21/17
02/21
14:18
02/21/17
14:18
Technical Analysis
NASDAQ Market Internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:17
02/21/17
02/21
14:17
02/21/17
14:17
Technical Analysis
NYSE Market Internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBI

Pitney Bowes

$13.74

0.35 (2.61%)

14:11
02/21/17
02/21
14:11
02/21/17
14:11
Options
Bullish option flow in Pitney Bowes »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

HD

Home Depot

$144.01

1.0148 (0.71%)

14:08
02/21/17
02/21
14:08
02/21/17
14:08
Recommendations
Home Depot analyst commentary  »

Home Depot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 15

    Mar

EXAS

Exact Sciences

$19.91

-0.26 (-1.29%)

14:08
02/21/17
02/21
14:08
02/21/17
14:08
Upgrade
Exact Sciences rating change  »

Exact Sciences upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

AG

First Majestic

$9.86

-0.2 (-1.99%)

14:06
02/21/17
02/21
14:06
02/21/17
14:06
Options
First Majestic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DVA

DaVita

$68.36

1.46 (2.18%)

, CI

Cigna

$145.74

2.18 (1.52%)

14:02
02/21/17
02/21
14:02
02/21/17
14:02
Hot Stocks
HealthCare Partners, Cigna form alliance to deliver new health plans in L.A. »

HealthCare Partners, a…

DVA

DaVita

$68.36

1.46 (2.18%)

CI

Cigna

$145.74

2.18 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AJG

Arthur J. Gallagher

$56.41

-0.53 (-0.93%)

14:00
02/21/17
02/21
14:00
02/21/17
14:00
Hot Stocks
Arthur J. Gallagher acquires Kelly Financial, terms not disclosed »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXAS

Exact Sciences

$19.91

-0.26 (-1.29%)

13:55
02/21/17
02/21
13:55
02/21/17
13:55
Recommendations
Exact Sciences analyst commentary  »

Craig-Hallum would still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

IMPV

Imperva

$45.70

0.8 (1.78%)

, CHKP

Check Point

$101.21

0.21 (0.21%)

13:51
02/21/17
02/21
13:51
02/21/17
13:51
Periodicals
Homeland Security having problems with computer systems, Reuters reports »

Some U.S. Department of…

IMPV

Imperva

$45.70

0.8 (1.78%)

CHKP

Check Point

$101.21

0.21 (0.21%)

SYMC

Symantec

$28.80

0.33 (1.16%)

PANW

Palo Alto Networks

$154.58

-0.18 (-0.12%)

QLYS

Qualys

$35.60

1.35 (3.94%)

FFIV

F5 Networks

$143.35

0.11 (0.08%)

FTNT

Fortinet

$37.46

0.215 (0.58%)

CUDA

Barracuda

$23.93

-0.07 (-0.29%)

FEYE

FireEye

$11.83

0.48 (4.23%)

PFPT

Proofpoint

$81.84

0.31 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 03

    Mar

  • 05

    Mar

K

Kellogg

$74.11

1.21 (1.66%)

13:51
02/21/17
02/21
13:51
02/21/17
13:51
Options
Hefty call spread in Kellogg as shares rally »

Hefty call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DBD

Diebold

$29.60

-0.5 (-1.66%)

13:47
02/21/17
02/21
13:47
02/21/17
13:47
Conference/Events
Diebold to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MNK

Mallinckrodt

$53.66

-1.0799 (-1.97%)

13:46
02/21/17
02/21
13:46
02/21/17
13:46
Options
Mallinckrodt call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

HAS

Hasbro

$98.50

0.86 (0.88%)

13:45
02/21/17
02/21
13:45
02/21/17
13:45
Conference/Events
Hasbro management to meet with Wells Fargo »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

KFY

Korn/Ferry

$30.46

-0.1498 (-0.49%)

, GSK

GlaxoSmithKline

$41.50

0.16 (0.39%)

13:44
02/21/17
02/21
13:44
02/21/17
13:44
Hot Stocks
Korn Ferry Futurestep partners with GlaxoSmithKline over talent acquisition »

Futurestep division of…

KFY

Korn/Ferry

$30.46

-0.1498 (-0.49%)

GSK

GlaxoSmithKline

$41.50

0.16 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

13:35
02/21/17
02/21
13:35
02/21/17
13:35
General news
NY Fed accepted $163.3 B in daily reverse repos »

NY Fed accepted $163.3 B…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.